10x Genomics
TXG
51.80
-5.58
-9.72%
10x Genomics
US · TXG
#1311 by market cap
Listed 2019
51.80
-5.58
-9.72%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 61 in the most recent period (2026/Q3).
- Total institutional ownership rose 4.4 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 101.51% +4.44pp
- Institutions
- 525 +61
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund82.30%
Hedge Fund9.04%
Individual/Insider7.72%
Public Company6.10%
VC/PE Fund1.36%
Government Pension Fund0.71%
Family Office/Trust0.66%
Private Company0.66%
Insurance Company0.46%
Top holders as of 2026-09-30
FMR
14.47% · 19.03M sh
T. Rowe Price Group, Inc.
11.64% · 15.31M sh
BlackRock
8.80% · 11.57M sh
ARK Investment Management LLC
4.77% · 6.27M sh
Vanguard Portfolio Management, LLC
4.50% · 5.91M sh
Quantinno Capital Management LP
4.16% · 5.48M sh
Vanguard Capital Management, LLC
4.10% · 5.39M sh
Serge Saxonov
3.13% · 4.11M sh
Amova Asset Management
3.22% · 4.19M sh
Benjamin Hindson
2.53% · 3.32M sh
Morgan Stanley
2.49% · 3.27M sh
Geode Capital Management, LLC
2.37% · 3.08M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 11 buys · 38 sells
| Name | Role | Stake |
|---|---|---|
| Serge Saxonov | Chief Executive Officer | 3.13% |
| Benjamin Hindson | Co-Founder, President, Chief Scientific Officer & Director | 2.53% |
| John Stuelpnagel | Independent Chairperson | 1.85% |
| Adam Taich | CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | 0.08% |
| Alan Mateo | Independent Director | 0.05% |
| Sridhar Kosaraju | Independent Director | 0.05% |
| Kimberly Popovits | Independent Director | 0.02% |
| Shehnaaz Suliman | Independent Director | 0.01% |
| Sarah Teichmann | -- | 0.01% |
| Joseph Gilliam | Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-09 | Serge Saxonov | Chief Executive Officer | Open Market Disposition | -31,000 | $62.90 |
| 2026-10-27 | Joseph Gilliam | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-09-21 | Shehnaaz Suliman | Independent Director | Automatic Disposition | -5,723 | $78.20–82.28 |
| 2026-09-21 | Serge Saxonov | Chief Executive Officer | Automatic Disposition | -25,000 | $78.23–82.37 |
| 2026-09-08 | Adam Taich | CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | Automatic Disposition | -46,388 | $63.68–65.26 |
| 2026-09-02 | John Stuelpnagel | Independent Chairperson | Open Market Disposition | -20,000 | $60.66–62.61 |
| 2026-08-31 | Serge Saxonov | Chief Executive Officer | Other Disposition | -100 | -- |
| 2026-08-25 | Serge Saxonov | Chief Executive Officer | Automatic Disposition | -10,486 | $63.02–64.75 |
| 2026-08-23 | Shehnaaz Suliman | Independent Director | Automatic Disposition | -2,207 | $62.73–63.97 |
| 2026-08-23 | Adam Taich | CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | Open Market Disposition | -17,166 | $63.02 |
| 2026-08-23 | Serge Saxonov | Chief Executive Officer | Open Market Disposition | -18,545 | $63.02 |
| 2026-08-23 | Benjamin Hindson | Co-Founder, President, Chief Scientific Officer & Director | Open Market Disposition | -13,818 | $63.02 |
| 2026-08-19 | Serge Saxonov | Chief Executive Officer | Other Disposition | -4,000 | -- |
| 2026-08-13 | Sarah Teichmann | -- | Automatic Disposition | -7,551 | $57.15–57.29 |
| 2026-08-13 | Sarah Teichmann | -- | Intent to Sell (Form 144) | -2,273 | $57.15 |
| 2026-08-12 | Sarah Teichmann | -- | Intent to Sell (Form 144) | -5,278 | $57.29 |
| 2026-08-10 | John Stuelpnagel | Independent Chairperson | Open Market Disposition | -20,000 | $57.58–58.73 |
| 2026-06-21 | Serge Saxonov | Chief Executive Officer | Automatic Disposition | -30,000 | $33.29–36.16 |
| 2026-06-15 | Shehnaaz Suliman | Independent Director | Automatic Disposition | -5,723 | $32.59–33.27 |
| 2026-06-03 | Kimberly Popovits | Independent Director | Other Acquisition | +8,829 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.
10x Genomics discussion 0 comments